



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 08/700,565      | 07/25/1996  | MICHEAL L. GRUENBERG | 6870-500B           | 4491             |

24961 7590 07/30/2002

HELLER EHRMAN WHITE & MCAULIFFE LLP  
4250 EXECUTIVE SQ  
7TH FLOOR  
LA JOLLA, CA 92037

EXAMINER

SCHWADRON, RONALD B

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1644

DATE MAILED: 07/30/2002

43

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.  
08/700,565

Applicant(s)  
Gruenberg

Examiner  
Ron Schwadron, Ph.D.

Art Unit  
1644



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_\_
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 22-25, 28, 29, 31-33, 155-158, 162, 164-168, 170-172, 211-213 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 22-25, 28, 29, 31-33, 155-158, 162, 164-168, 170-172, 211-213, 216 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☐ Other:

1. Regarding applicants comments in page 2, third paragraph of the amendment filed 5/17/2002, the Examiner is following the appropriate course of action as indicated by the MPEP section 714.03. The MPEP section 714.03 (August 2001, page 700-176, first column, first paragraph) states:

*If an amendment submitted after March 1, 2001, fails to comply with 37 CFR 1.121 (as revised on September 8, 2000), **the Office will notify applicant by a Notice of Non-Compliant Amendment, that the amendment fails to comply with the requirements of 37 CFR 1.121** and applicant will be given a period of time in which to comply with the rule. If the amendment that fails to comply with the requirements of the rule is a preliminary amendment, the Legal Instruments Examiner (LIE) will send the Notice which sets a time limit of 30 days or one month, whichever is later, for reply. No extensions of time are permitted. Failure to submit a timely reply will result in the application being examined without entry of the preliminary amendment. If the amendment which fails to comply with the requirements of the rule is an amendment after a non-final Office action, the LIE will send the Notice which sets a time limit of 30 days or one month, whichever is later, for reply (37 CFR 1.135). Extensions of time are permitted (37 CFR 1.136(a)). Failure to reply to this Notice will result in abandonment of the application.*

2. Claims 22-25,28,29,31-33,155-158,162, 164-168,170-172,211-213,216,217 are under consideration. Claims 1,4,6,8-13,15,26,27,30,34,35,159-161,163,169,173-210,215,215 have been canceled. Claims 22-25,28,155,157,158,211 have been amended.

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 22-25,28,29,31-33,155-158,162,164-168,170-172 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the

specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no support in the specification as originally filed for the recitation of "in the absence of IL-2" in claim 22. The specification discloses the method of claim 22 with the limitation "in the absence of *exogenous* IL-2". However, the instant limitation encompasses the absence of endogenous IL-2 (eg. produced in response to mitogenic antibodies), wherein such a method is not disclosed in the specification as originally filed. There is no written description of the scope of the claimed invention in the specification as originally filed (eg. the claimed invention constitutes new matter).

There is no support in the specification as originally filed for the recitation of " $10^{10}$  cells/liter of a homogenous population of Th1 cells, wherein a homogenous population of Th1 cells comprises greater than about 50% Th1 cells" in claim 22. Applicant has not indicated where said limitation finds support in the specification as originally filed. There appears to be no support in the specification as originally filed for the particular concentration of said Th1 at the degree of purity recited in said claim. There is no written description of the scope of the claimed invention in the specification as originally filed (eg. the claimed invention constitutes new matter).

There is no support in the specification as originally filed for the recitation of "in the absence of exogenous cytokines" in claim 155 or 157. The specification discloses the claimed method practiced "in the absence of exogenous IL-2", but does not disclose the scope of the instant limitation wherein the method recites absence of any exogenous cytokine. There is no written description of the scope of the claimed invention in the specification as originally filed (eg. the claimed invention constitutes new matter).

5. Claims 22-25, 28, 29, 31-33, 155-158, 162, 164-168, 170-172, 211-213, 216, 217 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification does not provide adequate written description of the claimed invention. The legal standard for sufficiency of a patent's (or a specification's) written description is whether that description "reasonably conveys to the artisan that the inventor

had possession at that time of the . . . claimed subject matter", *Vas-Cath, Inc. v. Mahurkar*, 19 U.S.P.Q.2d 1111 (Fed. Cir.

1991). In the instant case, the specification does not convey to the artisan that the applicant had possession at the time of invention of the invention as recited in the claims.

The instant claims encompass a method that uses an agent that can be used to differentiate leukocytes into Th1 cells. The instant claims encompass a method that uses agents per se to expand Th1. However, the only specific agents to induce Th1 differentiation disclosed in the specification are treatment with antiIL-4 antibody or interferon gamma or IL-12. The only specific agents disclosed in the specification to expand Th1 are specific mitogenic antibodies as recited in claim 32. The claims encompass use of a wide variety of undisclosed agents in the claimed method. In view of the aforementioned problems regarding description of the claimed invention, the specification does not provide an adequate written description of the invention claimed herein. See *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398, 1404-7 (Fed. Cir. 1997). In *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (Fed. Cir. 1995) the inventors claimed a genus of DNA species encoding insulin in different vertebrates or mammals, but had only described a single species of cDNA which encoded rat insulin. The court held that only the nucleic acids species described in the specification (i.e. nucleic acids encoding rat insulin) met the description requirement and that the inventors were not entitled to a claim encompassing a genus of nucleic acids encoding insulin from other vertebrates, mammals or humans, *id.* at 1240. In the instant case, the facts are similar to those disclosed in *University of California v. Eli Lilly and Co.* The Federal Circuit has held that if an inventor is "unable to envision the detailed constitution of a gene so as to distinguish it from other materials. . . conception has not been achieved until reduction to practice has occurred", *Amgen, Inc. v. Chugai Pharmaceutical Co, Ltd.*, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991). Attention is also directed to the decision of *The Regents of the University of California v. Eli Lilly and Company* (CAFC, July 1997) wherein is stated: The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 222 USPQ 369, 372-373 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, naming a type of material generally

known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material.

Thus, as we have previously held, a cDNA is not defined or described by the mere name "cDNA," even if accompanied by the name of the protein that it encodes, but requires a kind of specificity usually achieved by means of the recitation of the sequence of nucleotides that make up the cDNA. See *Fiers*, 984 F.2d at 1171, 25 USPQ2d at 1606.

6. Regarding priority for the claims 22-25,28,29,31-33, 155-158,162,164-168,170-172 with regards to the application of prior art, the claimed inventions are not disclosed in parent application provisional application 60/044693 (the application formerly known as 08/506668), and therefore priority with regards to the application of prior art is taken as the filing date of PCT WO 97/052349 to which applicant claims priority. For example, there is no disclosure in 60/044693 of the method of claim 22 for generating Th1 per se (60/044693 refers to methods of generating autologous Th1 lymphoid cells). There is no disclosure in parent application provisional application 60/044693 of the method of claim 22, parts b and c. Claim 1 in 60/044693 is restricted to a method that uses mitogenic monoclonal antibodies. Regarding claim 155, there is no disclosure in parent 60/044693 of the use of "two or more activating proteins specific for cell surface proteins" (eg. the disclosure of 60/044693 is limited to use of mitogenic monoclonal antibodies). Also, there is no disclosure in parent 60/044693 of the claimed method that recites "absence of exogenous cytokines".

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

8. Claims 22-25, 28, 211, 216 are rejected under 35 U.S.C. 102(e) as being anticipated by Babbitt et al. (US Patent 5,766,920). Applicants arguments have been considered and deemed not persuasive.

Babbitt et al. teach methods for producing Th1 cells, wherein patient mononuclear cells are removed and expanded in vitro (see columns 5 and 6) and used for autologous cell therapy (see abstract). Babbitt et al. teach that said cells can be grown in the absence of IL-2 (see column 17, last paragraph). The method taught by Babbitt et al. uses IFN  $\gamma$  enriched supernatants and OKT3 (eg. antiCD3 antibody) to produce Th1 populations (see columns 5 and 6). The administered OKT3 consists of "mitogenic monoclonal antibodies" (eg. multiple copies of the same antibody). Babbitt et al. teach that autologous expanded Th1 cells are reinfused to treat autoimmune disease (see column 2, first complete paragraph). The cells are expanded to clinically relevant numbers (see column 19). The cells are treated with two or more activating proteins specific for cell surface proteins found on the Th1 (eg. T3CS (see column 5)). The cells are purified from the material (see column 8, penultimate paragraph). The cells can be specific for a particular antigen (see claim 12). Babbitt et al. teach expansion to  $10^9$  cells and infusion of said cells into a patient (see column 19, penultimate paragraph) wherein said number of cells is encompassed by "about  $10^{10}$  cells". Babbitt et al. teach that the cells grown at a final concentration of  $10^7$  cells/ml and that  $10^9$  cells were administered (eg. the  $10^9$  cells would have been present in 100 mls of media, see column 19, penultimate paragraph). Babbitt et al. teach that the cell population produced is at least 75% Th1 (eg. said population could be homogenous).

Regarding applicants comments, while Babbitt et al. teach that their method can be used to expand a variety of different T cell populations, Babbitt et al. also teach that their method can specifically be used to expand Th1 type cells (see column 6, penultimate paragraph). The Th1 cells are not an intermediate cell that is used to produce T3CS but are a final product that is administered to humans to treat disease (see column 6, penultimate paragraph, last sentence). Babbitt et al. teach that mononuclear cells are used as the starting material in said method (eg. see column 5, first incomplete paragraph) wherein mononuclear cells are a "leukocyte containing material" or a "material containing mononuclear T lymphoid cells". The method of expanding Th1 disclosed in column 5, first incomplete paragraph does not use IL-2. Regarding applicants comments about mitogenic antibodies, claim 22 does not recite use of mitogenic antibodies. Regarding claim 211,

said claim recites use of "mitogenic monoclonal antibodies", but does not recite that the antibodies are different.

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. Claims 22-25,28,33,211-213,217 are rejected under 35 U.S.C. § 103 as being unpatentable over Babbitt et al. (US Patent 5,766,920) in view of Cracauer et al. (US Patent 4,804,628).

Babbitt et al. teach methods for producing Th1 cells, wherein patient mononuclear cells are removed and expanded in vitro (see columns 5 and 6) and used for autologous cell therapy (see abstract). Babbitt et al. teach that said cells can be grown in the absence of IL-2 (see column 17, last paragraph). The method taught by Babbitt et al. uses IFN  $\gamma$  enriched supernatants and OKT3 (eg. antiCD3 antibody) to produce Th1 populations (see columns 5 and 6). The administered OKT3 consists of "mitogenic monoclonal antibodies" (eg. multiple copies of the same antibody). Babbitt et al. teach that autologous expanded Th1 cells are reinfused to treat autoimmune disease (see column 2, first complete paragraph). The cells are expanded to clinically relevant numbers (see column 19). The cells are treated with two or more activating proteins specific for cell surface proteins found on the Th1 (eg. T3CS (see column 5)). The cells are purified from the material (see column 8, penultimate paragraph). The cells can be specific for a particular antigen (see claim 12). Babbitt et al. teach expansion to  $10^9$  cells and infusion of said cells into a patient (see column 19, penultimate paragraph) wherein said number of cells is encompassed by "about  $10^{10}$  cells". Babbitt et al. teach that the cells grown at a final concentration of  $10^7$  cells/ml and that  $10^9$  cells were administered (eg. the  $10^9$  cells would have been present in 100 mls of media, see column 19, penultimate paragraph). Babbitt et al. teach that the cell population produced is at least 75% Th1 (eg. said population could be homogenous). Babbitt et al. do not teach the use of a hollow fiber bioreactor in said method. Cracauer et al. teach hollow fiber bioreactors and that the use of such hollow fiber bioreactors for



efficiently growing larger numbers of cells in vitro (see columns 1-3). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because Babbitt et al. teach the claimed method except for the use of a hollow fiber bioreactor and Cracauer et al. teach hollow fiber bioreactors and that the use of such hollow fiber bioreactors for efficiently growing larger numbers of cells in vitro. A routineer would have grown larger numbers of cells than  $10^9$  in order to obtain larger numbers of cells in order to ascertain the optimal dosage to use to obtain the desired clinical effect in any particular type of treated disease. One of ordinary skill in the art would have been motivated to do the aforementioned because Cracauer et al. teach that "hollow fiber culture devices have been proven to be ideal for the maintenance of many types of cells at high densities in culture." (column 1).

Applicants comments regarding Babbitt et al. are addressed in paragraph 8 of this Office Action.

11. Claims 22-25, 28, 29, 31, 211, 216 are rejected under 35 U.S.C. § 103 as being unpatentable Babbitt et al. (US Patent 5,766,920) in view of Garra et al.

Babbitt et al. teach methods for producing Th1 cells, wherein patient mononuclear cells are removed and expanded in vitro (see columns 5 and 6) and used for autologous cell therapy (see abstract). Babbitt et al. teach that said cells can be grown in the absence of IL-2 (see column 17, last paragraph). The method taught by Babbitt et al. uses IFN  $\gamma$  enriched supernatants and OKT3 (eg. antiCD3 antibody) to produce Th1 populations (see columns 5 and 6). The administered OKT3 consists of "mitogenic monoclonal antibodies" (eg. multiple copies of the same antibody). Babbitt et al. teach that autologous expanded Th1 cells are reinfused to treat autoimmune disease (see column 2, first complete paragraph). The cells are expanded to clinically relevant numbers (see column 19). The cells are treated with two or more activating proteins specific for cell surface proteins found on the Th1 (eg. T3CS (see column 5)). The cells are purified from the material (see column 8, penultimate paragraph). The cells can be specific for a particular antigen (see claim 12). Babbitt et al. teach expansion to  $10^9$  cells and infusion of said cells into a patient (see column 19, penultimate paragraph) wherein said number of cells is encompassed by "about  $10^{10}$  cells". Babbitt et al. teach that the cells grown at a final concentration of  $10^7$  cells/ml and that  $10^9$  cells were administered (eg. the  $10^9$  cells would have been present in 100 mls of media, see column 19, penultimate paragraph). Babbitt et al. teach that the cell

population produced is at least 75% Th1 (eg. said population could be homogenous). Babbitt et al. do not teach the use of a hollow fiber bioreactor in said method. Babbitt et al. do not teach use of anti-IL-4 antibody in said method. O'Garra et al. teach that stimulation of CD4+ cells in the presence of IL-2 or antiCD3 leads to the development of Th1 cells (eg. see page 460, second column). O'Garra et al. teach that anti-IL-4 antibody treatment of CD4+ cells favors the development of Th1 (see page 460, first column). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because Babbitt et al. disclose a method that produces Th1 cells, while O'Garra et al. teach that stimulation of CD4+ cells in the presence of IL-2 or antiCD3 leads to the development of Th1 cells and that anti-IL-4 antibody treatment of CD4+ cells favors the development of Th1 (see page 460, first column). One of ordinary skill in the art would have been motivated to do the aforementioned because O'Garra et al. teach that anti-IL-4 antibody treatment of CD4+ cells favors development of Th1 cells.

Regarding applicants comments, O'Garra et al., page 460, second column teach: *"In our system, using the OVA-specific TCR-transgenic mouse as a source of CD4+ T cells, stimulation of CD4+ Mel-14low population with antigen, in the presence of anti-IL-4 Mabs or IL-12, as compared with a medium control, induced the development of Th1 cells producing very high levels of IFN- $\gamma$  upon restimulation (SE Macatonia and A O'Garra, unpublished data), in agreement with the studies of Romagnani et al. ..."*

12. Claim 32 is rejected under 35 U.S.C. 103(a) as being unpatentable over Babbitt et al. (US Patent 5,766,920) in view of Garra et al. as applied to claims 22-25,28,29,31,211,216 above, and further in view of June et al. (WO 94/29436) or (US Patent 5,855,358) for the reasons elaborated in the previous Office Action. Applicants arguments have been considered and deemed not persuasive.

Applicants arguments are addressed above.

13. Claims 22-25,31,32,155-158,164,165,167,168,211,212 are rejected under 35 U.S.C. 102(e) as being anticipated by June et al. (US Patent 6,352,694).

June et al. teach that Th1 cells can be produced and expanded using treatment of CD4+ cells with antiCD3 antibody and antiCD28 antibody (see column 30, penultimate paragraph). Said method does not use exogenous lymphokines. June et al. teach that the

CD4+ cells used can be antigen specific (see column 30, first complete paragraph). The antiCD3 and antiCD28 antibodies taught by June et al. are mitogenic monoclonal antibodies (see Example 14). The cells can be further isolated or purified (see column 19). The starting material can be T cells isolated from PBL (see column 19). The cells can be expanded to reach  $10^{11}$  cells (see column 28, lines 1-5). The cells are homogenous because June et al. teach that this method selectively expands Th1 cells (see column 30, penultimate paragraph).

14. Claims 22-25, 31-33, 155-158, 164-168, 170-172, 211-213, 216, 217 are rejected under 35 U.S.C. § 103 as being unpatentable over June et al. (US Patent 6,352,694) in view of Cracauer et al. (US Patent 4,804,628).

June et al. teach that Th1 cells can be produced/differentiated and expanded using treatment of CD4+ cells with antiCD3 antibody and antiCD28 antibody (see column 30, penultimate paragraph). Said method does not use exogenous lymphokines. June et al. teach that the CD4+ cells used can be antigen specific (see column 30, first complete paragraph). The antiCD3 and antiCD28 antibodies taught by June et al. are mitogenic monoclonal antibodies (see Example 14). The cells can be further isolated or purified (see column 19). The starting material can be T cells isolated from PBL (see column 19). The cells can be expanded to reach  $10^{11}$  cells (see column 28, lines 1-5). The cells are homogenous because June et al. teach that this method selectively expands Th1 cells (see column 30, penultimate paragraph). June et al. do not teach the use of a hollow fiber bioreactor in said method. Cracauer et al. teach hollow fiber bioreactors and that the use of such hollow fiber bioreactors for efficiently growing larger numbers of cells in vitro (see columns 1-3). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because June et al. teach the claimed method except for the use of a hollow fiber bioreactor and Cracauer et al. teach hollow fiber bioreactors and that the use of such hollow fiber bioreactors for efficiently growing larger numbers of cells in vitro. Regarding the various concentrations of cells disclosed in the claims, June et al. disclose that the cells can be expanded to reach  $10^{11}$  cells (see column 28, lines 1-5). Said cells would have been adjusted to any desired concentration depending on the use of said cells. One of ordinary skill in the art would have been motivated to do the aforementioned because Cracauer et al. teach that "hollow fiber culture devices have been proven to be ideal for the maintenance of many types of cells

at high densities in culture."(column 1).

15. Claims 22-25,31,32,155-158,162,164,165,167,168,211,212 are rejected under 35 U.S.C. 103(a) as being unpatentable over June et al. (US Patent 6,352,694) in view of Sedar et al.

June et al. teach that Th1 cells can be produced and expanded using treatment of CD4+ cells with antiCD3 antibody and antiCD28 antibody (see column 30, penultimate paragraph). Said method does not use exogenous lymphokines. June et al. teach that the CD4+ cells used can be antigen specific (see column 30, first complete paragraph). The antiCD3 and antiCD28 antibodies taught by June et al. are mitogenic monoclonal antibodies (see Example 14). The cells can be further isolated or purified (see column 19). The starting material can be T cells isolated from PBL (see column 19). The cells can be expanded to reach  $10^{11}$  cells (see column 28, lines 1-5). The cells are homogenous because June et al. teach that this method selectively expands Th1 cells (see column 30, penultimate paragraph). June et al. do not teach treatment with interferon gamma. Seder et al. teach that Th1 (eg. interferon gamma producing cells derived from CD4+ T cells) can be produced by treating CD4+ cells with interferon gamma (see page 10190, second column, last paragraph, first sentence). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because June et al. teach the claimed method except for the use of interferon gamma treatment, while Seder et al. teach that Th1 (eg. interferon g producing cells derived from CD4+ T cells) can be produced by treating CD4+ cells with interferon gamma (see page 10190, second column, last paragraph, first sentence).

16. No claim is allowed.

17. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.

18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-

Serial No. 08/700565  
Art Unit 1644

12

4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

  
RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1600-1644

Ron Schwadron, Ph.D.  
Primary Examiner  
Art Unit 1644